Table 3 Associations between metformin use at hospital admission for AMI and MACE over median follow-up of 343 (IQR 1–1436) days using propensity score analysis
Endpoint | Hazard ratio (95% CI) | P value |
|---|---|---|
Primary endpoint | ||
 MACE (composite of cardiovascular mortality, AMI and stroke) | 1.13 (1.03–1.23) | 0.006 |
Components of primary endpoint | ||
 Cardiovascular mortality | 1.12 (1.00–1.25) | 0.044 |
 AMI | 1.07 (0.95–1.21) | 0.273 |
 Stroke | 1.00 (0.83–1.21) | 0.977 |
Secondary endpoints | ||
 All-cause mortality | 1.02 (0.94–1.11) | 0.660 |
 HF hospitalisation | 1.18 (1.06–1.31) | 0.002 |